Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises in connection with the sale of Fiskarhedenvillan
Mandate

Vinge advises in connection with the sale of Fiskarhedenvillan

March 17, 2020 M&A

Vinge has advised Litorina and other shareholders in connection with the sale of Fiskarhedenvillan to the company’s CEO and a group of industrial partners.

Fiskarhedenvillan sells residential properties primarily to private individuals in Sweden, Denmark and Finland and has a turnover of approximately SEK 700 million on an annual basis.

Vinge’s team primarily consisted of Johan Winnerblad, Joacim Rydergård, Anna Thoms, Olivia Belding, Rikard Lindahl, William Kåge, Louise Brorsson Salomon and Viktoria Owetz Leyva.

Related

Vinge advised Precise Biometrics

 Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

 Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026